Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Rivaroxaban, an oral factor XA inhibitor, has been approved for reducing the risk of stroke in patients with atrial fibrillation (AF). The drug joins dabigatran (Pradaxa) as the second "nonwarfarin" oral anticoagulant approved for this indication.

Rivaroxaban Tablets (Xarelto®)